Stocks and Investing
Stocks and Investing
Thu, January 2, 2020
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tue, December 31, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Mon, December 30, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Fri, December 27, 2019
[ 12:00 AM ] - United States, WOPRAI
Thu, December 26, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tue, December 24, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Anupam Rama Initiated (YMAB) at Buy and Held Target at $39 on, Dec 24th, 2019
Anupam Rama of JP Morgan, Initiated "Y-mAbs Therapeutics, Inc." (YMAB) at Buy and Held Target at $39 on, Dec 24th, 2019.
Anupam has made no other calls on YMAB in the last 4 months.
There is 1 other peer that has a rating on YMAB. Out of the 1 peers that are also analyzing YMAB, 0 agree with Anupam's Rating of Hold.
This is the rating of the analyst that currently disagrees with Anupam
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $43 on, Tuesday, October 29th, 2019
Contributing Sources